PDL BioPharma (PDLI) Sees Q2 Revs Ahead of Views
Tweet Send to a FriendGet Alerts PDLI Hot Sheet
Price: $8.22 +0.49%
EPS Growth %: +4.0%
Financial Fact:
Operating income: 84.66M
Today's EPS Names:
LBIX, ESEA, ISS, More
EPS Growth %: +4.0%
Financial Fact:
Operating income: 84.66M
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade PDLI Now!
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced royalty revenue guidance for the second quarter ending June 30, 2012, of approximately $125 million, as compared with actual royalty revenue of $122 million for the second quarter of 2011, a two percent increase.
The Street sees revs of $122.1 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The Street sees revs of $122.1 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Wal-mart (WMT) Posts Q1 EPS of $1.14; U.S. Comps Down 1.4%; Guides Q2 EPS
- Autodesk, Inc. (ADSK) Misses Q1 EPS by 3c, Offers Guidance
- QAD (QADA) Slumpc on Cut Q1 Outlook
Create E-mail Alert Related Categories
Guidance, Hot Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
